Alberto Briganti

1 month ago | acsjournals.onlinelibrary.wiley.com | Wataru Fukuokaya |Keiichiro Mori |Takafumi Yanagisawa |Fumihiko Urabe |Pawel Rajwa |Alberto Briganti | +4 more

Jan 10, 2025 | europeanurology.com | Mattia Longoni |Alberto Briganti |Giorgio Gandaglia |Francesco Montorsi

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy b“Vita-Salute” San Raffaele University, Milan, Italy Publication History: Accepted January 2, 2025; Published online January 10,...

Dec 19, 2024 | ejso.com | Simone Albisinni |Luca Orecchia |Georges Mjaess |Fouad Aoun |Francesco Del Giudice |Luca Antonelli | +10 more

Review ArticleArticles in Press109543 1Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy 2Department of Urology, Hopital Universitaire de Bruxelles, Universite’ Libre de Bruxelles, Bruxelles, Belgium 3Faculty of Medicine, Hôtel-Dieu de France, Saint-Joseph University, Beirut, Lebanon 4Department of Urology, Policlinico Umberto I, Sapienza University, Rome, Italy 5Department of Urology, Kantonsspital Luzern, Lucerne,...

Nov 14, 2024 | urotoday.com | Alberto Briganti

Read the Full Video TranscriptAlberto Briganti: Well, thank you very much, dear moderators, and thank you, Silke and Aurelius, for this very kind invitation to defend, in a way, surgery in the setting of high-risk prostate cancer as a part of a multimodal approach. These are my disclosures. So why should we consider surgery in this setting?

Dec 11, 2023 | europeanurology.com | Antonio Cigliola |Valentina Tateo |Carlo Bosi |Alberto Briganti

Vale CL, Fisher DJ, Godolphin PJ, et al. Lancet Oncol 2023;24:783–97The meta-analysis by Vale and colleagues reports the effects of docetaxel added to androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) according to patient characteristics. The authors proved that docetaxel prolongs overall survival (OS) in patients with poorer prognosis (high-volume [HV] disease and “bulky” T4 stage tumor).